ClinicalTrials.gov
public full text
Public Domain
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease#917338
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population#686248
- Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus#448203
- An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders#258766
- Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.#421127
Record · ID 892945
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive